{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:48:17Z","timestamp":1761094097867,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1774,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.bbmt.2010.01.016","type":"journal-article","created":{"date-parts":[[2010,2,5]],"date-time":"2010-02-05T04:18:41Z","timestamp":1265343521000},"page":"848-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?"],"prefix":"10.1016","volume":"16","author":[{"given":"Yuzhen","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongrong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schwarzenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaochuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jicheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.01.016_bib1","first-page":"1497","article-title":"A minute chromosome in human chronic granulo-cytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.01.016_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2010.01.016_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European Leukemia Net. Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.01.016_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukaemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib5","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib8","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.01.016_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib13","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib15","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloidleukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bmt.2008.218","article-title":"Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase","volume":"42","author":"Bittencourt","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:SCT or TKIs?","volume":"42","author":"Ruiz-Arguelles","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.leu.2404534","article-title":"Do affluent societies have the only options for the best therapy?","volume":"21","author":"GajewskiJL","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.01.016_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bmt.2008.265","article-title":"Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis","volume":"43","author":"Lai","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.01.016_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","article-title":"The probability of long-term leukaemia free survival for patients in molecular remission 5years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase","volume":"115","author":"Mughal","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.01.016_bib26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2002-01-0048","article-title":"A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies","volume":"100","author":"Couban","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2001-12-0304","article-title":"Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia","volume":"100","author":"Schmitz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.2004.04943.x","article-title":"Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients","volume":"125","author":"Tanimoto","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib29","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib30","first-page":"426","article-title":"Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia","volume":"23","author":"Liu","year":"2004","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.bbmt.2010.01.016_bib31","first-page":"389","article-title":"HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases","volume":"26","author":"He","year":"2005","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib32","first-page":"424","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia: 118 cases analysis","volume":"20","author":"Liu","year":"1999","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.bbmt.2010.01.016_bib33","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib34","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.01.016_bib35","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10428190601078464","article-title":"Allogeneic stem-cell transplantation provides excellent results in dvanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy","volume":"48","author":"Weisser","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.01.016_bib37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/10428190802626624","article-title":"Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia","volume":"50","author":"Poir\u00e9","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.01.016_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1701607","article-title":"Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation","volume":"23","author":"Steegmann","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","article-title":"Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease","volume":"10","author":"Posthuma","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.01.016_bib41","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib42","first-page":"3328","article-title":"Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"95","author":"Guglielmi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.01.016_bib43","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.01.016_bib44","first-page":"663","article-title":"A comparison of donor lymphocyte infusion or imatinib mesylate for patients with chronic mylogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.01.016_bib45","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.01.016_bib46","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:37:27Z","timestamp":1761057447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1083879110000455"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.01.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}